-
MitMAB for Polarity-Aware EV Uptake Studies
2026-10-01
MitMAB enables controlled investigation of dynamin-dependent uptake in polarized intestinal models. This article explains how to use N,N,N-trimethyltetradecan-1-aminium bromide to distinguish epithelial orientation, vesicle internalization, and downstream trafficking effects.
-
Iron Lipid Peroxidation in Sickle Cell AKI
2026-10-01
A 2026 reference study links rhabdomyolysis-induced acute kidney injury in sickle cell mice to renal iron accumulation, lipid peroxidation, and weakened antioxidant defenses. Its intervention data suggest that deferiprone, ferrostatin-1, and hydroxyurea can reduce oxidative renal injury, while also highlighting the limits of translating prophylactic mouse findings to human sickle cell disease.
-
KU-55933 ATM Kinase Inhibitor Workflow
2026-09-30
Build a controlled KU-55933 workflow that connects ATM signaling, phospho-Akt Ser473, G1 arrest, and metabolic phenotypes in cancer models. The approach also adapts the personalized control logic of an iPSC prescreening study without implying that the reference study tested KU-55933.
-
Reading m6A Biology Through RNA Capture
2026-09-30
A translational framework for connecting arginine methylation, SMN–METTL14 biology, and m6A homeostasis with defined biotinylated RNA experiments.
-
Macrophage EV miR-660 Drives Breast Cancer Metastasis
2026-09-29
This study identifies a macrophage-derived extracellular-vesicle mechanism in which miR-660 promotes breast cancer invasion and metastasis by disrupting KLHL21 regulation of the IKKβ/NF-κB p65 axis. Its combination of patient-tissue analysis, cellular transfer experiments, and mouse metastasis models provides a useful framework for studying tumor–immune-cell communication in cancer biology research.
-
Viral RIPK3 Degradation and Necroptotic Inflammation
2026-09-29
The reference study identifies a viral inducer of RIPK3 degradation, or vIRD, that recruits host SCF machinery to drive ubiquitination and proteasome-dependent loss of the necroptosis kinase. Genetic analysis in poxvirus systems and mice shows that vIRD links viral replication, RIPK3–MLKL signaling, inflammation, and pathogen–host evolution.
-
Sulforaphane Limits PM2.5-Driven COPD Injury
2026-09-28
A 2026 study reports that sulforaphane attenuates PM2.5-associated lung injury in experimental COPD models, linking antioxidant Nrf2 activity with suppression of EGFR/PI3K/AKT signaling. Its combination of animal and cell experiments, network pharmacology, molecular docking, and EGFR silencing offers a mechanistic framework, although the available report does not establish clinical efficacy or provide enough protocol detail to reproduce exposure conditions.
-
MLKL Polymers Trigger Lysosomal Permeabilization
2026-09-26
The study identifies MLKL polymerization-induced lysosomal membrane permeabilization as an execution step in necroptosis, occurring before plasma membrane rupture. Imaging and cathepsin B perturbation experiments connect lysosomal damage to cytosolic protease release and cell death, refining the mechanism by which activated MLKL drives necroptosis.
-
Deferiprone: Iron-Chelation Workflows for Research
2026-09-26
Deferiprone offers a practical way to test whether iron availability contributes to oxidative injury, apoptosis, or altered cell behavior. This guide connects a recent sickle cell kidney-injury study to adaptable cell and animal workflows, with clear handling and troubleshooting guidance.
-
Esculetin Limits CKLF1-Linked Inflammation After Stroke
2026-09-25
A mouse study links esculetin’s post-stroke benefits to reduced CKLF1–CCR5 signaling and neutrophil recruitment, combining behavioral, imaging, tissue, and cell-based evidence. The findings support CKLF1-mediated inflammation as a candidate mechanism for recovery research, while leaving clinical efficacy and direct molecular targeting unresolved.
-
Cisplatin (CDDP): Mechanisms and Research Use
2026-09-25
Cisplatin (CDDP) is a DNA-crosslinking chemotherapeutic used in cancer research to study DNA damage, apoptosis, and tumor response. A 2023 study also reports that pharmacological SMYD2 inhibition reduced cisplatin-associated renal injury and fibrosis in experimental models, an important boundary when interpreting its biological effects.
-
SmD2 Acetylation Shapes HCC Splicing and PARP Response
2026-09-24
This study identifies SmD2, a core spliceosome protein, as an acetylation-regulated factor that connects cassette-exon choice with DNA repair and PARP inhibitor sensitivity in hepatocellular carcinoma. Its findings support a testable combination strategy involving HDAC inhibition and PARP inhibition, while highlighting the need to validate the mechanism and treatment response across HCC models.
-
From Podocyte Injury to Translational Renal Models
2026-09-24
Puromycin aminonucleoside is more than a nephrotoxic challenge: it is a tool for connecting podocyte structure, filtration failure, and disease-relevant readouts. This article outlines how to use the model strategically, interpret its limits, and build a more translational evidence chain.
-
HyperFluor 488 Goat Anti-Mouse IgG for ATII Assays
2026-09-23
Build sensitive ATII-cell assays around a fluorescently labeled secondary antibody that connects mitochondrial imaging with flow cytometry and immunoblot validation. This workflow translates hyperoxia-induced DRP1 and glycolytic changes into practical staining, signal-control, and troubleshooting decisions.
-
MLN8237 and Aurora A: From Mitosis to Immunity
2026-09-23
MLN8237 (Alisertib) offers a precise way to interrogate Aurora A biology across mitosis, apoptosis, tumor growth, and trained immunity. Integrating product pharmacology with Li et al.’s 2025 findings on SAM metabolism, this article presents a translational framework for connecting kinase inhibition to chromatin state, inflammatory memory, and cancer response—while clearly separating established evidence from testable hypotheses.